2025
Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society–USA Panel
Gandhi R, Landovitz R, Sax P, Smith D, Springer S, Günthard H, Thompson M, Bedimo R, Benson C, Buchbinder S, Crabtree-Ramirez B, del Rio C, Eaton E, Eron J, Hoy J, Lehmann C, Molina J, Jacobsen D, Saag M. Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society–USA Panel. JAMA 2025, 333: 609-628. PMID: 39616604, DOI: 10.1001/jama.2024.24543.Peer-Reviewed Original ResearchAntiretroviral drugsHIV preventionSubstance use disordersLong-acting injectable therapyManagement of HIV infectionIntegrase strand transfer inhibitorsNucleotide reverse transcriptase inhibitorsStrand transfer inhibitorsSexually transmitted infectionsPeer-reviewed scientific conferencesDaily oral medicationReverse transcriptase inhibitorsLong-acting medicationsManagement of substance use disordersPrevention of HIVCardiovascular disease preventionTreating substance use disordersVirological failureAntiretroviral therapyHIV acquisitionHIV infectionHIV exposureInjection therapyDaily therapyLaboratory monitoring
2023
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
Gandhi R, Bedimo R, Hoy J, Landovitz R, Smith D, Eaton E, Lehmann C, Springer S, Sax P, Thompson M, Benson C, Buchbinder S, del Rio C, Eron J, Günthard H, Molina J, Jacobsen D, Saag M. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. JAMA 2023, 329: 63-84. PMID: 36454551, DOI: 10.1001/jama.2022.22246.Peer-Reviewed Original ResearchConceptsPrevention of HIVAntiretroviral therapySubstance use disordersAntiretroviral drugsUse disordersCertain antiretroviral medicationsDaily oral regimenInhibitor-containing regimensManagement of comorbiditiesMonkeypox virus infectionDiagnosis of HIVSARS-CoV-2 pandemicCare of peopleGlobal health emergencyInitial therapyOral regimenAdherence supportMetabolic complicationsPreexposure prophylaxisViral suppressionAntiretroviral medicationsOral medicationsHIV infectionLaboratory monitoringInjectable therapies
2022
Dolutegravir hypersensitivity reaction: the need for strengthening pharmacovigilance systems with optimization of antiretroviral therapy in HIV programs in resource-limited settings (case report)
Adeiza M, Kekulah I, Wachekwa I, Ogbuagu O. Dolutegravir hypersensitivity reaction: the need for strengthening pharmacovigilance systems with optimization of antiretroviral therapy in HIV programs in resource-limited settings (case report). PAMJ Clinical Medicine 2022, 8 DOI: 10.11604/pamj-cm.2022.8.47.33930.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAdverse drug reactionsDrug reactionsHIV programsResource-limited settingsAntiretroviral therapyHypersensitivity reactionsAdvanced HIV diseaseLamivudine/tenofovirLamivudine/zidovudineRoutine laboratory monitoringCombination antiretroviral therapyAntiretroviral drug treatmentFirst-line cARTFeatures of anaphylaxisRelevant health educationDrug discontinuityViral suppressionHIV diseaseHIV infectionBlood workOpportunistic infectionsLaboratory monitoringNew symptomsDrug treatmentMedical treatment
2020
Clinical Research in Hepatology in the COVID‐19 Pandemic and Post‐Pandemic Era: Challenges and the Need for Innovation
Verna EC, Serper M, Chu J, Corey K, Fix OK, Hoyt K, Page KA, Loomba R, Li M, Everson GT, Fried MW, Garcia‐Tsao G, Terrault N, Lok AS, Chung RT, Reddy KR. Clinical Research in Hepatology in the COVID‐19 Pandemic and Post‐Pandemic Era: Challenges and the Need for Innovation. Hepatology 2020, 72: 1819-1837. PMID: 32740969, PMCID: PMC7435542, DOI: 10.1002/hep.31491.Peer-Reviewed Original ResearchConceptsClinical researchInvestigational productAcute respiratory syndrome coronavirus 2 pandemicSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemicChronic liver diseaseLong-term followCoronavirus 2 pandemicClinical trial designImplementation of telemedicineHepatitis BLiver diseaseLaboratory monitoringClinical careTrial designCoronavirus disease 2019 (COVID-19) researchNatural historyCompletion of studyTherapeutic developmentNational InstituteCOVID-19 pandemicHepatologyOngoing studiesDiseaseIndustry fundingPandemicCOVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up JACC State-of-the-Art Review
Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, Der Nigoghossian C, Ageno W, Madjid M, Guo Y, Tang LV, Hu Y, Giri J, Cushman M, Quéré I, Dimakakos EP, Gibson CM, Lippi G, Favaloro EJ, Fareed J, Caprini JA, Tafur AJ, Burton JR, Francese DP, Wang EY, Falanga A, McLintock C, Hunt BJ, Spyropoulos AC, Barnes GD, Eikelboom JW, Weinberg I, Schulman S, Carrier M, Piazza G, Beckman JA, Steg PG, Stone GW, Rosenkranz S, Goldhaber SZ, Parikh SA, Monreal M, Krumholz HM, Konstantinides SV, Weitz JI, Lip GYH, Global COVID-19 Thrombosis Collaborative Group E. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up JACC State-of-the-Art Review. Journal Of The American College Of Cardiology 2020, 75: 2950-2973. PMID: 32311448, PMCID: PMC7164881, DOI: 10.1016/j.jacc.2020.04.031.Peer-Reviewed Original ResearchConceptsAntithrombotic therapyThrombotic diseaseCOVID-19Outcomes of patientsViral respiratory illnessEndothelial dysfunctionArterial thrombosisThromboembolic diseaseExcessive inflammationRespiratory illnessLaboratory monitoringJACC StateArterial circulationPlatelet activationPatientsCoronavirus diseaseDiseaseTherapyCOVID-19 pandemicPreventionCurrent understandingThromboticThrombosisInflammationDysfunction
2017
Idiopathic T cell lymphopenia identified in New York State Newborn Screening
Albin-Leeds S, Ochoa J, Mehta H, Vogel BH, Caggana M, Bonagura V, Lehman H, Ballow M, Rubinstein A, Siegel S, Weiner L, Weinberg GA, Cunningham-Rundles C. Idiopathic T cell lymphopenia identified in New York State Newborn Screening. Clinical Immunology 2017, 183: 36-40. PMID: 28694137, PMCID: PMC5736366, DOI: 10.1016/j.clim.2017.07.002.Peer-Reviewed Original ResearchConceptsT-cell receptor excision circlesT-cell lymphopeniaCD3 countsCell lymphopeniaLow T cell receptor excision circlesIdiopathic T-cell lymphopeniaAbsolute CD3 countState referral centerOutcomes of patientsAppropriate laboratory monitoringT cell valuesIdentification of infantsClinical characteristicsMost patientsReferral centerAdditional infantsRetrospective reviewExcision circlesLaboratory monitoringState newborn screeningImmune deficiencyNewborn screeningInfantsLymphopeniaPatients
2016
Laboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies
Ouattara EN, Robine M, Eholié SP, MacLean RL, Moh R, Losina E, Gabillard D, Paltiel AD, Danel C, Walensky RP, Anglaret X, Freedberg KA. Laboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies. Clinical Infectious Diseases 2016, 62: 1454-1462. PMID: 26936666, PMCID: PMC4872286, DOI: 10.1093/cid/ciw117.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioAntiretroviral therapyHuman immunodeficiency virusImmunologic failureLaboratory monitoringAIDS Complications-International modelFirst-line antiretroviral therapyBudget impactSecond-line antiretroviral therapyMean CD4 countStandard of careCost-effectiveness ratioLaboratory test costsCD4 monitoringART initiationCD4 countHIV infectionVL monitoringClinical outcomesImmunodeficiency virusCôte d'IvoireMean timeLife expectancyTherapyVL strategies
2014
The Guidelines Battle on Starting Statins
D'Agostino RB, Ansell BJ, Mora S, Krumholz HM. The Guidelines Battle on Starting Statins. New England Journal Of Medicine 2014, 370: 1652-1658. PMID: 24758622, DOI: 10.1056/nejmclde1314766.Peer-Reviewed Original Research
2013
Dabigatran and Kidney Disease: A Bad Combination
Knauf F, Chaknos CM, Berns JS, Perazella MA. Dabigatran and Kidney Disease: A Bad Combination. Clinical Journal Of The American Society Of Nephrology 2013, 8: 1591-1597. PMID: 23868901, PMCID: PMC3805067, DOI: 10.2215/cjn.01260213.Peer-Reviewed Original ResearchConceptsAnticoagulant effectPharmacokinetic profileOral direct thrombin inhibitorContinuous renal replacement therapyRoutine laboratory monitoringSerious bleeding eventsHigh bleeding riskReduced kidney functionRenal replacement therapyDirect thrombin inhibitorDrug Administration approvalLaboratory monitoring testsBleeding eventsBleeding riskSerious bleedingThromboembolic complicationsDose adjustmentHemodialysis cathetersKidney functionKidney diseaseReplacement therapyLaboratory monitoringAdministration approvalClinical indicationsDrug levels
2002
Triglyceride, cholesterol and weight changes among risperidone-treated youths
Martin A, L'Ecuyer S. Triglyceride, cholesterol and weight changes among risperidone-treated youths. European Child & Adolescent Psychiatry 2002, 11: 129-133. PMID: 12369772, DOI: 10.1007/s00787-002-0255-5.Peer-Reviewed Original ResearchConceptsRisperidone-treated youthsMean ageWeight gainRetrospective chart reviewWeight changeRegular laboratory monitoringAtypical antipsychotic useSignificant weight gainSample mean ageChart reviewRisperidone doseAntipsychotic useSerum triglyceridesLaboratory monitoringTriglyceride levelsCholesterol levelsLipid dysregulationAdolescent inpatientsTriglyceridesPreliminary reportMeasures analysisSuch associationsCholesterolSignificant changesAverage length
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply